ZEAB Therapeutic engages Cresset Discovery Services to progress treatment for colorectal cancer
Cambridge, UK – 21 July 2020 – Cresset Discovery Services, a CRO for early phase discovery, has used computational tools ...
BioFocus DPI takes global license for Cresset’s molecular field software. “BioFocus DPI and Cresset BioMolecular Discovery announced today that BioFocus DPI has up-graded its software license with Cresset to provide global access to the entire range of Cresset’s molecular field software for use in drug discovery”.
BioFocus DPI and Cresset BioMolecular Discovery announced today that BioFocus DPI has up-graded its software license with Cresset to provide global access to the entire range of Cresset’s molecular field software for use in drug discovery. BioFocus DPI and Cresset have been working together for two years on the design and synthesis of BioFocus DPI’s FieldFocus™ libraries, focused libraries for ion channel drug discovery. The success of these libraries in generating hit series validates Cresset’s approach and its use in the design of novel biologically focused libraries. The new license also extends BioFocus DPI’s coverage to include its parent company, Galapagos. BioFocus DPI and Galapagos will now have the facility to apply molecular field technology to their projects, whether internal research, library design or drug discovery projects for clients. Beatrice Leigh, CEO of Cresset, commented ‘We have built a close working relationship with BioFocus DPI over the last two years and have a great respect for each other’s technologies and skills. We are delighted to further cement this relationship with the lease of the entire range of Cresset’s software to BioFocus DPI and its parent company, Galapagos.’
“The FieldFocus libraries we have developed using Cresset’s molecular field software have been particularly successful in identifying novel hit-series for ligand-gated ion channels. We are pleased to continue applying Cresset’s technology to develop new FieldFocus libraries and to further contribute to our clients’ medicinal chemistry projects,” said Chris Newton, Senior Vice President of BioFocus DPI.
BioFocus DPI’s aim is to expand partners’ drug pipeline by accelerating the gene-tocandidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools. As the service division of Galapagos, BioFocus DPI has over 300 employees in five countries worldwide. More information about BioFocus DPI can be found at www.biofocusdpi.com.
Cresset BioMolecular Discovery Ltd develops technology and software for calculating and exploiting the molecular field characteristics of molecules. Field technology provides a ‘protein’s view’ of a ligand, facilitating hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s current product line includes FieldTemplaterTM for finding the bioactive field template, FieldScreenTM for virtual screening, FieldAlignTM for aligning molecules to a field template and XedexTM for exploring conformational space. More information about Cresset can be found at www.cresset-bmd.com.
Chris Newton, Senior Vice President
Tel: +44 1799 533500
Cresset BioMolecular Discovery Ltd.
Sally Rose, Director of Business Development
Tel: +44 1707 356120